{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:41:38Z","timestamp":1777909298225,"version":"3.51.4"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The protozoan Trypanosoma cruzi is auxotrophic for purines and causes Chagas\u2019 disease (CD), a neglected illness affecting &amp;gt;6 million people. Combining the 3-deoxyribofuranose part of cordycepin with the modified purine ring of a nucleoside \u2018hit\u2019 led to the discovery of 4-amino-5-(4-chlorophenyl)-N7-(3\u2032-deoxy-\u03b2-d-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (Cpd1), revealing promising anti-T. cruzi activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To further evaluate Cpd1\u2002in vitro and in vivo to fully assess its therapeutic potential against CD, covering cell culture sterilization through washout assays, drug combination with benznidazole and long-term administration in T. cruzi-infected mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Although less susceptible to Cpd1 than amastigotes, trypomastigotes present an impaired capacity to successfully establish intracellular infection of cardiac cultures. Combination of benznidazole with Cpd1 indicated no interaction (additive effect) (FIC index\u2009=\u20090.72) while administration to mice at one-tenth of the optimal dose (2.5\u2009mg\/kg and 10\u2009mg\/kg for Cpd1 and benznidazole, respectively) suppressed parasitaemia but failed to avoid mortality. Long-term treatment (60\u2009days) gave a rapid drop of the parasitaemia (&amp;gt;98% decline) and 100% mice survival but only 16% cure. In vitro washout experiments demonstrated that although parasite release into the supernatant of infected cardiac cultures was reduced by &amp;gt;94%, parasite recrudescence did occur after treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Parasite recrudescence did occur after treatment corroborating the hypothesis of therapeutic failure due to subpopulations of dormant forms and\/or genetic factors in persister parasites involved in natural drug resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlab168","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:17:13Z","timestamp":1636546633000},"source":"Crossref","is-referenced-by-count":9,"title":["7-Aryl-7-deazapurine 3\u2032-deoxyribonucleoside derivative as a novel lead for Chagas\u2019 disease therapy: <i>in vitro<\/i> and <i>in vivo<\/i> pharmacology"],"prefix":"10.1093","volume":"3","author":[{"given":"Camila","family":"Cardoso-Santos","sequence":"first","affiliation":[{"name":"Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC\/FIOCRUZ), 21040-360 Rio de Janeiro, RJ, Brazil"},{"name":"Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Wilrijk, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila","family":"Ferreira de Almeida Fiuza","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC\/FIOCRUZ), 21040-360 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane","family":"Fran\u00e7a da Silva","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC\/FIOCRUZ), 21040-360 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Lia","family":"Mazzeti","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC\/FIOCRUZ), 21040-360 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberson","family":"Donola Gir\u00e3o","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC\/FIOCRUZ), 21040-360 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Melo de Oliveira","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC\/FIOCRUZ), 21040-360 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"da Gama Jaen Batista","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC\/FIOCRUZ), 21040-360 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otacilio","family":"Cruz Moreira","sequence":"additional","affiliation":[{"name":"Real Time PCR Platform RPT09A, Laboratory of Molecular Biology and Endemic Diseases, Oswaldo Cruz Institute (IOC\/FIOCRUZ), Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nat\u00e1lia","family":"Lins da Silva Gomes","sequence":"additional","affiliation":[{"name":"Real Time PCR Platform RPT09A, Laboratory of Molecular Biology and Endemic Diseases, Oswaldo Cruz Institute (IOC\/FIOCRUZ), Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Maes","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Wilrijk, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-3202","authenticated-orcid":false,"given":"Guy","family":"Caljon","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Wilrijk, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Hulpia","sequence":"additional","affiliation":[{"name":"Laboratory for Medicinal Chemistry (Campus Heymans), Ghent University, Ottergemsesteenweg 460, 9000 Gent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge V","family":"Calenbergh","sequence":"additional","affiliation":[{"name":"Laboratory for Medicinal Chemistry (Campus Heymans), Ghent University, Ottergemsesteenweg 460, 9000 Gent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria de Nazar\u00e9","family":"Correia Soeiro","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC\/FIOCRUZ), 21040-360 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"2021111805212402100_dlab168-B1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1590\/S0074-02762009000900006","article-title":"Epidemiology, control and surveillance of Chagas disease:- 100 years after its discovery","volume":"104","author":"Coura","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2021111805212402100_dlab168-B2","author":"World Health Organization"},{"key":"2021111805212402100_dlab168-B3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.idc.2012.03.002","article-title":"American trypanosomiasis (Chagas disease)","volume":"26","author":"Rassi","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"2021111805212402100_dlab168-B4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/0037-8682-0505-2016","article-title":"2nd Brazilian Consensus on Chagas disease, 2015","volume":"49","author":"Dias","year":"2016","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021111805212402100_dlab168-B5","doi-asserted-by":"crossref","first-page":"e12786","DOI":"10.1111\/pim.12786","article-title":"Host-parasite dynamics in Chagas disease from systemic to hyper-local scales","volume":"43","author":"P\u00e9rez-Mazliah","year":"2021","journal-title":"Parasite Immunol"},{"key":"2021111805212402100_dlab168-B6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5334\/gh.891","article-title":"COVID-19: implications for people with Chagas disease","volume":"15","author":"Zaidel","year":"2020","journal-title":"Glob Heart"},{"key":"2021111805212402100_dlab168-B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1590\/0074-02760150352","article-title":"Spatial distribution of triatomines in domiciles of an urban area of the Brazilian Southeast region","volume":"111","author":"Dias","year":"2016","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2021111805212402100_dlab168-B8","author":"Drugs for Neglected Diseases Initiative"},{"key":"2021111805212402100_dlab168-B9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1191\/0960327106het653oa","article-title":"Toxic side effects of drugs used to treat Chagas\u2019 disease (American trypanosomiasis)","volume":"25","author":"Castro","year":"2006","journal-title":"Hum Exp Toxicol"},{"key":"2021111805212402100_dlab168-B10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4269\/ajtmh.15-0256","article-title":"Safety profile of nifurtimox and treatment interruption for chronic chagas disease in Colombian adults","volume":"93","author":"Olivera","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2021111805212402100_dlab168-B11","author":"Drugs for Neglected Diseases Initiative. Disease Factsheet"},{"key":"2021111805212402100_dlab168-B12","doi-asserted-by":"crossref","first-page":"e01135-20","DOI":"10.1128\/AAC.01135-20","article-title":"Adverse events associated with nifurtimox treatment for Chagas disease in children and adults","volume":"65","author":"Berenstein","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2021111805212402100_dlab168-B13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pt.2003.09.001","article-title":"Specific chemotherapy of Chagas disease: controversies and advances","volume":"19","author":"Urbina","year":"2003","journal-title":"Trends Parasitol"},{"key":"2021111805212402100_dlab168-B14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1021\/acsinfecdis.8b00298","article-title":"Drug discovery for kinetoplastid diseases: future directions","volume":"5","author":"Rao","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2021111805212402100_dlab168-B15","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.2174\/092986710791556023","article-title":"Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy?","volume":"17","author":"Berg","year":"2010","journal-title":"Curr Med Chem"},{"key":"2021111805212402100_dlab168-B16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1550-7408.1979.tb04657.x","article-title":"Purine metabolism in trypanosomatids","volume":"26","author":"Ceron","year":"1979","journal-title":"J Protozool"},{"key":"2021111805212402100_dlab168-B17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"2021111805212402100_dlab168-B18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(02)00788-X","article-title":"Nucleoside analogues and nucleobases in cancer treatment","volume":"3","author":"Galmarini","year":"2002","journal-title":"Lancet Oncol"},{"key":"2021111805212402100_dlab168-B19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1271\/nogeikagaku1924.66.1349","article-title":"Nucleoside analogues","volume":"66","author":"Seki","year":"1992","journal-title":"Nippon Nogeikagaku Kaishi"},{"key":"2021111805212402100_dlab168-B20","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1021\/acsinfecdis.0c00105","article-title":"Structure-activity relationship exploration of 3\u2032-deoxy-7-deazapurine nucleoside analogues as anti- Trypanosoma brucei agents","volume":"6","author":"Hulpia","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2021111805212402100_dlab168-B21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1515\/ap-2017-0070","article-title":"In vitro effects of purine and pyrimidine analogues on Leishmania donovani and Leishmania infantum promastigotes and intracellular amastigotes","volume":"62","author":"Azzouz","year":"2017","journal-title":"Acta Parasitol"},{"key":"2021111805212402100_dlab168-B22","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1021\/acs.jmedchem.9b01275","article-title":"Discovery of pyrrolo[2,3- b]pyridine (1,7-dideazapurine) nucleoside analogues as anti- Trypanosoma cruzi agents","volume":"62","author":"Lin","year":"2019","journal-title":"J Med Chem"},{"key":"2021111805212402100_dlab168-B23","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1021\/acs.jmedchem.8b00999","article-title":"Discovery of novel 7-aryl 7-deazapurine 3\u2032-deoxy-ribofuranosyl nucleosides with potent activity against Trypanosoma cruzi","volume":"61","author":"Hulpia","year":"2018","journal-title":"J Med Chem"},{"key":"2021111805212402100_dlab168-B24","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/AAC.01617-09","article-title":"Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas\u2019 disease treatment","volume":"54","author":"Batista","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021111805212402100_dlab168-B25","first-page":"198","article-title":"Interaction of Trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro","volume":"41","author":"Meirelles","year":"1986","journal-title":"Eur J Cell Biol"},{"key":"2021111805212402100_dlab168-B26","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1017\/S0031182014000407","article-title":"In vitro investigation of the efficacy of novel diamidines against Trypanosoma cruzi","volume":"141","author":"Timm","year":"2014","journal-title":"Parasitology"},{"key":"2021111805212402100_dlab168-B27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1590\/S0074-02762010000200022","article-title":"In vitro and in vivo experimental models for drug screening and development for Chagas disease","volume":"105","author":"Romanha","year":"2010","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2021111805212402100_dlab168-B28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1590\/S0074-02762009000800001","article-title":"Inhibition of Trypanosoma cruzi proline racemase affects host-parasite interactions and the outcome of in vitro infection","volume":"104","author":"Coutinho","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2021111805212402100_dlab168-B29","doi-asserted-by":"crossref","first-page":"e02205-17","DOI":"10.1128\/AAC.02205-17","article-title":"In vitro, in silico, and in vivo analyses of novel aromatic amidines against Trypanosoma cruzi","volume":"62","author":"Santos","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021111805212402100_dlab168-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2021111805212402100_dlab168-B31","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/jac\/dkv495","article-title":"Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis","volume":"71","author":"Trinconi","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021111805212402100_dlab168-B32","doi-asserted-by":"crossref","first-page":"e2000","DOI":"10.1371\/journal.pntd.0002000","article-title":"Analytical performance of a multiplex real-time PCR assay using TaqMan probes for quantification of Trypanosoma cruzi satellite DNA in blood samples","volume":"7","author":"Duffy","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2021111805212402100_dlab168-B33","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1128\/AAC.01667-15","article-title":"In vitro and in vivo trypanosomicidal action of novel arylimidamides against Trypanosoma cruzi","volume":"60","author":"Guedes-Da-Silva","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021111805212402100_dlab168-B34","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3201\/eid1503.081597","article-title":"Forgotten people, forgotten diseases: the neglected tropical diseases and their impact on global health and development","volume":"15","author":"Ben Beard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2021111805212402100_dlab168-B35","doi-asserted-by":"crossref","first-page":"e0007962","DOI":"10.1371\/journal.pntd.0007962","article-title":"Central Latin America: two decades of challenges in neglected tropical disease control","volume":"14","author":"Hotez","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2021111805212402100_dlab168-B36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","article-title":"COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives","volume":"17","author":"Nishiga","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2021111805212402100_dlab168-B37","author":"Drugs for Neglected Dieseases Initiative"},{"key":"2021111805212402100_dlab168-B38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13063-020-4226-2","article-title":"Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial","volume":"21","author":"Molina-Morant","year":"2020","journal-title":"Trials"},{"key":"2021111805212402100_dlab168-B39","doi-asserted-by":"crossref","first-page":"e38\u201346","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice","volume":"20","author":"Lindner","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021111805212402100_dlab168-B40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"2021111805212402100_dlab168-B41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/JEP.S267378","article-title":"Review on experimental treatment strategies against Trypanosoma cruzi","volume":"13","author":"Mazzeti","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"2021111805212402100_dlab168-B42","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1038\/s41467-019-13522-6","article-title":"Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness","volume":"10","author":"Hulpia","year":"2019","journal-title":"Nat Commun"},{"key":"2021111805212402100_dlab168-B43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijpddr.2016.08.003","article-title":"Assessing anti-T. cruzi candidates in vitro for sterile cidality","volume":"6","author":"Cal","year":"2016","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2021111805212402100_dlab168-B44","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd4683","article-title":"Hit and lead criteria in drug discovery for infectious diseases of the developing world","volume":"14","author":"Katsuno","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2021111805212402100_dlab168-B45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/tropicalmed4020082","article-title":"Drug discovery for Chagas disease: impact of different host cell lines on assay performance and hit compound selection","volume":"4","author":"Franco","year":"2019","journal-title":"Trop Med Infect Dis"},{"key":"2021111805212402100_dlab168-B46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/acsinfecdis.8b00253","article-title":"Successful aspects of the coadministration of sterol 14\u03b1-demethylase inhibitor VFV and benznidazole in experimental mouse models of Chagas disease caused by the drug-resistant strain of Trypanosoma cruzi","volume":"5","author":"Guedes-da-Silva","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2021111805212402100_dlab168-B47","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/cmdc.202100144","article-title":"6-Methyl-7-aryl-7-deazapurine nucleosides as anti-Trypanosoma cruzi agents: structure-activity relationship and in vivo efficacy","volume":"16","author":"Lin","year":"2021","journal-title":"ChemMedChem"},{"key":"2021111805212402100_dlab168-B48","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1021\/acs.jmedchem.1c00135","article-title":"Revisiting pyrazolo[3,4-d]pyrimidine nucleosides as anti-Trypanosoma cruzi and antileishmanial agents","volume":"64","author":"Bouton","year":"2021","journal-title":"J Med Chem"},{"key":"2021111805212402100_dlab168-B49","first-page":"286","article-title":"Case 4\/2019 - 26-year-old man with congenital Chagas disease and heart transplantation","volume":"113","author":"Pinesi","year":"2019","journal-title":"Arq Bras Cardiol"},{"key":"2021111805212402100_dlab168-B50","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.pt.2015.06.006","article-title":"Reactivation of Chagas disease: implications for global health","volume":"31","author":"Perez","year":"2015","journal-title":"Trends Parasitol"},{"key":"2021111805212402100_dlab168-B51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov Today"},{"key":"2021111805212402100_dlab168-B52","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1371\/journal.pntd.0000720","article-title":"NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness","volume":"4","author":"Yun","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2021111805212402100_dlab168-B53","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","article-title":"Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial","volume":"6","author":"Musa","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2021111805212402100_dlab168-B54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jeu.12184","article-title":"Recent clinical trials for the etiological treatment of chronic Chagas disease: advances, challenges and perspectives","volume":"62","author":"Urbina","year":"2015","journal-title":"J Eukaryot Microbiol"},{"key":"2021111805212402100_dlab168-B55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00436-009-1637-0","article-title":"Acute Trypanosoma cruzi experimental infection induced renal ischemic\/reperfusion lesion in mice","volume":"106","author":"De Oliveira","year":"2009","journal-title":"Parasitol Res"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/4\/dlab168\/41162120\/dlab168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/4\/dlab168\/41162120\/dlab168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T08:11:00Z","timestamp":1637223060000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlab168\/6429833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlab168","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,9,30]]},"article-number":"dlab168"}}